Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bayer is in deal for clot drug

January 9, 2006 | A version of this story appeared in Volume 84, Issue 2

Bayer has entered a collaboration to codevelop Nuvelo's blood-clot-dissolving enzyme, alfimeprase, now in Phase III clinical trials. Bayer will pay the San Carlos, Calif., firm up to $385 million in milestone payments, including a $50 million up-front cash payment. Bayer will commercialize the product outside the U.S., while Nuvelo retains U.S. rights. Wolfgang Plischke, head of Bayer's pharmaceutical division, says the product complements his firm's existing hematology and cardiology portfolio.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.